TABLE 3.
Univariate analysis of OS
| Covariate | Category | Univariate analysis | |
|---|---|---|---|
| HR (95% CI) | p value | ||
| Sex | Female | 1.024 (0.702–1.495) | 0.900 |
| Age | ≥65 | 1.198 (0.844–1.700) | 0.313 |
| Histology | Adenocarcinoma | 1.368 (0.955–1.960) | 0.088 |
| Clinical stage | IV | 1.926 (1.143–3.246) | 0.014* |
| ECOG PS | 2–3 | 7.138 (4.311–11.818) | <0.001* |
| Smoking status | Former/current | 1.035 (0.739–1.450) | 0.839 |
| Number of metastatic sites | ≥3 | 1.359 (1.187–1.556) | <0.001* |
| Line of immunotherapy | ≥3 | 1.668 (1.193–2.330) | 0.003* |
| Liver metastases | Yes | 1.893 (1.255–2.855) | 0.002* |
| Brain metastases | Yes | 1.589 (1.087–2.323) | 0.017* |
| Bone metastases | Yes | 2.010 (1.425–2.836) | <0.001* |
| NLR | ≥3 | 3.878 (2.623–5.733) | <0.001* |
| ≥4 | 2.729 (1.936–3.847) | <0.001* | |
| dNLR | >3 | 2.522 (1.740–3.656) | <0.001* |
| LDH | >ULN | 2.640 (1.887–3.693) | <0.001* |
| >1.5*ULN | 4.554 (3.066–6.764) | <0.001* | |
| PLR | ≥160 | 1.382 (0.971–1.966) | 0.072 |
Abbreviations: dNLR, derived neutrophil‐to‐lymphocyte ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; NLR, neutrophil‐to‐lymphocyte ratio; OS, overall survival; PLR, platelet‐to‐lymphocyte ratio.
*
p < 0.05.